{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(3)"],"submitter":["Bartolomeo R"],"pubmed_abstract":["Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simu"],"journal":["Vaccines"],"pagination":["325"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975996"],"repository":["biostudies-literature"],"pubmed_title":["Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine."],"pmcid":["PMC10975996"],"pubmed_authors":["Troise F","Ruzza V","Garzia I","Vitale R","Cotugno G","Romano G","Sdruscia G","Bignone V","Allocca S","Siani L","Lanzaro F","Scarselli E","Petrone AM","D'Alise AM","Merone R","Colloca S","Leoni G","Bartolomeo R"],"additional_accession":[]},"is_claimable":false,"name":"Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.","description":"Quality control testing of vaccines, including potency assessment, is critical to ensure equivalence of clinical lots. We developed a potency assay to support the clinical advancement of Nous-209, a cancer vaccine based on heterologous prime/boost administration of two multivalent viral vector products: GAd-209 and MVA-209. These consist of a mix of four Adeno (Great Ape Adenovirus; GAd) and four Modified Vaccinia Ankara (MVA) vectors respectively, each containing a different transgene encoding a synthetic polypeptide composed of antigenic peptide fragments joined one after the other. The potency assay employs quantitative Reverse Transcription PCR (RT-Q-PCR) to quantitatively measure the transcripts from the four transgenes encoded by each product in in vitro infected cells, enabling simu","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-09T10:54:53.169Z","creation":"2025-04-04T19:11:13.994Z"},"accession":"S-EPMC10975996","cross_references":{"pubmed":["38543959"],"doi":["10.3390/vaccines12030325"]}}